English
Back
Download
Log in to access Online Inquiry
Back to the Top

Despite Hansoh Pharmaceutical's high P/E ratio, its minimal ...

Despite Hansoh Pharmaceutical's high P/E ratio, its minimal earnings growth and slower future growth vs. the market make its valuation questionable. Shareholders and investors may face disappointment as the high P/E isn't justified by the growth outlook.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more
Translate
Report
5254 Views
Comment
Sign in to post a comment